NEW YORK (GenomeWeb) – Two insurers have notified healthcare providers in their networks to discontinue using Myriad Genetics for BRCA testing.

In notes sent this week, Horizon Blue Cross Blue Shield of New Jersey and Amerigroup separately advised in-network providers to use only in-network laboratories for BRCA testing, a move that some investment analysts said could negatively impact Myriad.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.